ICCC ImmuCell CEO Paul te Boekhorst Stock Option Filing April 2026

Insider trading filings reveal what company leaders really think about their stock. When executives file ownership reports, investors pay attention. ImmuCell Corporation (ICCC) just disclosed a significant insider transaction involving its top executive. Paul Francis Olivier te Boekhorst, the President and CEO, filed an initial ownership report for non-qualified stock options. This filing shows 25,329 options with a strike price of $5.90 per share, valued at approximately $149,441. Understanding what insiders hold tells us plenty about confidence in the company’s future direction.

ImmuCell CEO Files Initial Stock Option Ownership Report

Paul Francis Olivier te Boekhorst, President and CEO of ICCC, filed an initial ownership report on November 7, 2025. The filing covers non-qualified stock options granted as part of his executive compensation package. This Form 3 filing represents the first official disclosure of his holdings in the company.

Understanding Form 3 Filings

Form 3 is the initial ownership statement filed by officers, directors, and major shareholders. It establishes a baseline of what insiders own when they first take their position. Unlike Form 4 filings that report changes in ownership, Form 3 simply documents the starting point. The SEC requires this filing within two business days of the insider taking office. For te Boekhorst, this filing confirms his initial equity stake in ImmuCell.

Non-Qualified Stock Options Explained

Non-qualified stock options (NSOs) give executives the right to purchase company shares at a fixed price. The strike price here is $5.90 per share. Te Boekhorst holds the right to buy 25,329 shares at this predetermined rate. NSOs differ from incentive stock options in tax treatment and flexibility. They represent a common form of executive compensation tied to company performance and shareholder value creation.

Transaction Details and Valuation

The insider transaction filing shows specific details about te Boekhorst’s stock option grant. The options cover 25,329 shares with a strike price of $5.90 per share. This creates an estimated total value of $149,441.10 based on the option parameters. The transaction date listed is September 16, 2028, indicating when these options were granted or became effective.

Strike Price and Exercise Value

The $5.90 strike price represents the cost per share if te Boekhorst exercises his options. This price was set when the options were granted. If ImmuCell’s stock trades above $5.90, the options gain intrinsic value. The difference between the current market price and strike price determines the option’s worth. At the time of this filing, the strike price reflects management’s view of fair value.

What This Valuation Means

The $149,441 estimated value represents the notional worth of these options. This is not cash compensation but rather the potential upside if options are exercised. Te Boekhorst must hold these options until they vest according to the grant agreement. The valuation shows the scale of equity incentives tied to his leadership role. Such grants align executive interests with long-term shareholder returns.

Insider Trading Signal and Market Implications

This initial ownership filing provides insight into executive compensation structure at ImmuCell. The grant of 25,329 options to the CEO represents significant equity participation. Such holdings typically indicate confidence in the company’s strategic direction. Meyka AI rates ICCC a grade of B, reflecting solid fundamentals and market positioning. The CEO’s substantial option grant aligns his interests with shareholder value creation.

What Initial Filings Tell Investors

Form 3 filings establish the baseline for tracking insider activity over time. Future Form 4 filings will show if te Boekhorst exercises, sells, or acquires additional shares. Investors use these filings to monitor whether insiders are buying or selling. The initial grant of options suggests the board values retaining top leadership. Regular monitoring of these filings helps investors understand management confidence levels.

ImmuCell’s Market Position

With a market cap of $72,012,520, ImmuCell operates in the competitive biotech sector. The CEO’s option grant reflects the company’s approach to executive retention. Stock-based compensation ties leadership performance to shareholder outcomes. This structure is standard across the biotech industry. Te Boekhorst’s significant option holdings demonstrate board confidence in his strategic vision.

SEC Filing Details and Compliance

The SEC filing was submitted on November 7, 2025, with a transaction date of September 16, 2028. This timing indicates the options were granted in September 2028 and formally disclosed in November 2025. The filing uses CIK number 0000811641 for ImmuCell Corporation. Te Boekhorst’s reporting CIK is 0002095704. All information is publicly available through the SEC’s EDGAR database.

Form 3 Filing Requirements

Insiders must file Form 3 within two business days of assuming their position. The form requires detailed disclosure of all securities owned or controlled. This includes stocks, options, warrants, and other equity instruments. Te Boekhorst’s filing lists his non-qualified stock options as the primary holding. Accurate and timely filing is mandatory under SEC regulations.

Tracking Insider Activity

Investors can monitor insider transactions through the SEC’s EDGAR system. Each filing creates a public record of executive holdings and transactions. Form 3 establishes the baseline for future Form 4 change reports. Regular review of these filings helps identify trends in insider behavior. Consistent buying by insiders often signals confidence, while selling may indicate concerns.

Final Thoughts

Paul Francis Olivier te Boekhorst’s Form 3 filing reveals ImmuCell’s approach to executive compensation through stock options. The 25,329 non-qualified options at $5.90 per share represent a $149,441 equity stake tied to his leadership. This initial ownership report establishes the baseline for tracking future insider activity at ICCC. The filing demonstrates the board’s commitment to aligning CEO interests with shareholder value creation. Investors should monitor subsequent Form 4 filings to track whether te Boekhorst exercises, acquires, or sells these options, as such activity provides valuable signals about management confidence in ImmuCell’s future performance.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Insider trading data is sourced from public SEC filings. This is not financial advice. Always conduct your own research and consult a licensed financial advisor before making investment decisions.